

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/237110 A1

(43) International Publication Date
25 November 2021 (25.11.2021)

(51) International Patent Classification:

A61P 1/04 (2006.01) C07K 16/28 (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:

PCT/US2021/033693

(22) International Filing Date:

21 May 2021 (21.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/029,085	22 May 2020 (22.05.2020)	US
63/066,705	17 August 2020 (17.08.2020)	US
63/071,264	27 August 2020 (27.08.2020)	US
63/088,147	06 October 2020 (06.10.2020)	US
63/121,088	03 December 2020 (03.12.2020)	US
63/144,939	02 February 2021 (02.02.2021)	US
21315068.3	21 April 2021 (21.04.2021)	EP

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US). **SANOFI BIOTECHNOLOGY** [FR/FR]; 54 rue La Boetie, 75008 Paris (FR).

(72) Inventors: **HAMILTON, Jennifer D.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MALONEY, Jennifer**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MANNENT, Leda**; c/o Sanofi Biotechnology, 54, rue La Boetie, 75008 Paris (FR). **RUDDY, Marcella**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 1591 (US).

(74) Agent: **SMITH, Ryan C.** et al.; Merchant & Gould P.C., P.O. Box 2903, Minneapolis, Minnesota 55402-0903 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR

(57) Abstract: The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of eosinophilic esophagitis in an adolescent or adult subject by administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) inhibitor, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

WO 2021/237110 A1